MENU
+Compare
ACRS
Stock ticker: NASDAQ
AS OF
Apr 2, 04:59 PM (EDT)
Price
$1.54
Change
+$0.06 (+4.05%)
Capitalization
87.95M

ACRS Aclaris Therapeutics Forecast, Technical & Fundamental Analysis

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States... Show more

ACRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ACRS with price predictions
Apr 01, 2025

ACRS's Stochastic Oscillator descends into oversold zone

The Stochastic Oscillator for ACRS moved into oversold territory on April 01, 2025. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Moving Average Convergence Divergence (MACD) for ACRS just turned positive on March 21, 2025. Looking at past instances where ACRS's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ACRS advanced for three days, in of 296 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 31, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ACRS as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACRS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ACRS entered a downward trend on March 26, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.573) is normal, around the industry mean (23.715). P/E Ratio (0.000) is within average values for comparable stocks, (83.458). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (2.837) is also within normal values, averaging (41.612).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ACRS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
ACRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ACRS is expected to report earnings to fall 87.12% to -13 cents per share on May 13

Aclaris Therapeutics ACRS Stock Earnings Reports
Q1'25
Est.
$-0.13
Q4'24
Missed
by $0.72
Q3'24
Missed
by $0.10
Q2'24
Beat
by $0.05
Q1'24
Beat
by $0.05
The last earnings report on February 27 showed earnings per share of -100 cents, missing the estimate of -28 cents. With 686.19K shares outstanding, the current market capitalization sits at 87.95M.
A.I. Advisor
published General Information

General Information

a manufacturer of novel dermatological therapies

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
701 Lee Road
Phone
+1 484 324-7933
Employees
91
Web
https://www.aclaristx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AMIGY37.640.64
+1.73%
Admiral Group Plc.
BAYRY6.050.03
+0.50%
Bayer A.G.
AAMCF0.50N/A
N/A
Altisource Asset Management Corp
EDPFY33.75-0.38
-1.11%
EDP S.A.
DSVSF1.43-0.05
-3.19%
Discovery Silver Corp.

ACRS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ACRS has been loosely correlated with PLLWF. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if ACRS jumps, then PLLWF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACRS
1D Price
Change %
ACRS100%
-3.27%
PLLWF - ACRS
64%
Loosely correlated
N/A
STRRP - ACRS
52%
Loosely correlated
+4.17%
MYNZ - ACRS
40%
Loosely correlated
-8.72%
UFPT - ACRS
39%
Loosely correlated
+1.10%
ANIK - ACRS
34%
Loosely correlated
N/A
More